Gland Pharma Limited, a leading injectable-focused pharmaceutical company, started December 12, 2024, on a high note as its shares surged on the back of a significant regulatory approval. The company’s stock opened higher on the National Stock Exchange (NSE) and reached an intraday peak of ₹1,864.
The United States Food and Drug Administration (USFDA) has granted approval to Gland Pharma for its Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. This product is a bioequivalent and therapeutically equivalent version of Hospira Inc.’s Vitamin K1 Injectable Emulsion USP. It is used to address coagulation disorders arising from vitamin K deficiency or interference with its activity.
According to industry data from IQVIA, the product recorded US sales of approximately USD 15 million for the twelve months ending September 2024. Gland Pharma plans to launch it in the US market soon through its marketing partners.
Established in 1978 in Hyderabad, Gland Pharma has grown from a small-volume liquid parenteral manufacturer to one of the largest injectable-focused companies globally. Operating under a business-to-business (B2B) model, the company serves over 60 countries, including the United States, Europe, Canada, and Australia.
Gland Pharma specialises in developing and manufacturing a wide range of sterile injectables, such as vials, ampoules, pre-filled syringes, and lyophilized vials. It also pioneered Heparin technology in India, strengthening its leadership position in the pharmaceutical industry.
Following the regulatory approval, Gland Pharma’s shares gained significant traction in the stock market. On December 12, 2024, the stock opened higher on the NSE and reached an intraday high of ₹1,864.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
